REGN REGENERON PHARMACEUTICALS, INC.

CIK 0000872589 48 ready 8-Ks latest July 30, 2026, 6:48 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 48

Latest filing July 30, 2026, 6:48 AM ET

Top materiality 0.90

Event mix earnings ×26 · other_material ×9 · other ×6

Sentiment 14 pos · 8 neg · 26 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for REGN

Highest-materiality recent filing

Regeneron to supply 1.4M additional REGEN-COV doses to U.S. Government for $2.94B

September 16, 2021, 7:59 PM ET other material materiality 0.90 positive item 1.01

Amendment obligates U.S. Government to buy 1.4 million doses at $2,100 each, totaling $2.94 billion.
Regeneron must deliver at least 100,000 doses per month (Sept–Dec 2021); all by January 31, 2022.

Read filing →

July 30, 2026, 6:48 AM ET earnings materiality 0.80 positive item 2.02 item 9.01

Regeneron Q2 2026 revenue up 17% to $4.3B; non-GAAP EPS $14.29 beats; Dupixent sales up 38%

Total revenues $4.291B (+17% YoY); GAAP EPS $12.23 (incl. $1.02 IPR&D charge); non-GAAP EPS $14.29 (+11%).
July 6, 2026, 7:00 AM ET other material materiality 0.65 negative item 2.02

Regeneron expects ~$127M IPR&D charge in Q2 2026, reducing EPS by ~$1.00

Pre-tax acquired IPR&D charge of ~$127M from collaboration and licensing up-front/opt-in payments.
April 29, 2026, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Regeneron Q1 revenue up 19% to $3.6B; non-GAAP EPS $9.47; gross margin guidance cut

Total revenues $3,605M (+19% YoY); GAAP EPS $6.75, non-GAAP EPS $9.47.
April 8, 2026, 7:59 PM ET earnings materiality 0.60 negative item 2.02 ◈ Earnings Releases

Regeneron expects ~$102M IPR&D charge in Q1 2026, ~$0.81 EPS hit

Pre-tax acquired IPR&D charge of ~$102M from milestone/up-front payments and equity securities premium.
January 30, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Regeneron Q4 rev $3.88B (+3%), GAAP EPS $7.86; Dupixent +34% to $4.9B

Q4 2025 total revenue $3.884B (+3% YoY); GAAP diluted EPS $7.86 (vs $8.06 Q4 2024); non-GAAP EPS $11.44 (vs $12.07).
October 28, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Regeneron Q3'25: Revenue $3.75B (+1%), GAAP EPS $13.62, Non-GAAP EPS $11.83; EYLEA sales down 28%

Total revenue $3.754B (+1% YoY); GAAP EPS $13.62 (+18%), non-GAAP EPS $11.83 (-5%).
August 1, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Regeneron Q2 revenue $3.68B (+4%), GAAP EPS $12.81, non-GAAP EPS $12.89; Dupixent sales +22%

Revenue $3.676B (+4% YoY); GAAP net income $1.392B, GAAP EPS $12.81 (+3%); non-GAAP EPS $12.89 (+12%).
April 29, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Regeneron Q1 revenue down 4%, non-GAAP EPS falls 14%; lowers gross margin guidance

Q1 2025 revenue $3.03B (-4% YoY); GAAP EPS $7.27 (+16%), non-GAAP EPS $8.22 (-14%).
February 4, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 8.01 item 9.01

Regeneron Q4 revenue up 10% to $3.79B; initiates $0.88 quarterly dividend, adds $3B buyback

Q4 GAAP diluted EPS $8.06 (-21% YoY); non-GAAP diluted EPS $12.07 (+2% YoY). Full year revenue $14.20B (+8%).
January 13, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Regeneron reports 2024 prelim EYLEA sales $6B; Libtayo >$1B; Dupixent >1M patients; pipeline updates

EYLEA HD and EYLEA aggregate U.S. net sales $6B for 2024 (+1% YoY); Q4 combined $1.5B (EYLEA HD $305M).
October 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Regeneron Q3 revenue up 11% to $3.72B; GAAP EPS $11.54; Dupixent sales +23%

Revenue $3.72B (+11% YoY); GAAP net income $1.34B, diluted EPS $11.54 (up 30%).
August 1, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Regeneron Q2 revenue up 12% to $3.55B, EPS beats; EU approves Dupixent for COPD

Total revenue $3.55B (+12% YoY); GAAP diluted EPS $12.41 (+46%); non-GAAP diluted EPS $11.56 (+13%).
May 2, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Regeneron Q1 revenue down 1% to $3.15B; Non-GAAP EPS $9.55; new $3B buyback

GAAP net income $722M ($6.27 diluted EPS) vs $818M ($7.17) YoY; Non-GAAP net income $1,116M ($9.55).
February 2, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Regeneron Q4 revenues $3.43B (+1% YoY); Dupixent up 31%; full-year guidance issued

Q4 GAAP EPS $10.19, non-GAAP $11.86; FY GAAP EPS $34.77, non-GAAP $43.79.
January 31, 2024, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 ◈ executive_change ×3

Regeneron appoints Christopher Fenimore as CFO to succeed retiring Robert Landry

Christopher Fenimore promoted to SVP, Finance and CFO; effective day after 2023 10-K filing (expected Feb 5, 2024).
January 8, 2024, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Regeneron reports preliminary Q4 U.S. EYLEA HD sales of $123M; IPR&D charge of $30M

Preliminary Q4 2023 U.S. net product sales: EYLEA HD $123M, EYLEA $1.34B, combined $1.46B.
November 2, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Regeneron Q3 revenue $3.36B (+15%); GAAP EPS $8.89, non-GAAP EPS $11.59; EYLEA HD launch begins

Revenue $3.363B (+15% YoY); GAAP EPS $8.89, non-GAAP EPS $11.59.
October 5, 2023, 7:59 PM ET other material materiality 0.65 negative item 2.02

Regeneron expects $100M pre-tax IPR&D charge in Q3 2023 from Alnylam milestone

Acquired IPR&D charge of $100M pre-tax due to clinical milestone for ALN-APP Alzheimer's program.
September 8, 2023, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 ◈ executive_change ×5

Regeneron CFO Landry to retire Feb 2024; Fenimore named successor; two new directors elected

Director Marc Tessier-Lavigne retired Sept 1, 2023 due to potential conflicts with other roles.
August 3, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Regeneron Q2 revenues up 11% to $3.16B; EPS $8.50 GAAP/$10.24 non-GAAP

Q2 2023 total revenues $3.158B (+11% YoY); GAAP diluted EPS $8.50 (up 14%); non-GAAP diluted EPS $10.24 (up 5%).
May 4, 2023, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Regeneron Q1 revenue up 7% to $3.16B; GAAP EPS $7.17; non-GAAP $10.09

Q1 total revenue $3.162B (+7% YoY); GAAP net income $818M (-16%); non-GAAP net income $1.168B (-11%).
April 17, 2023, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 ◈ executive_change ×4

Regeneron Chair P. Roy Vagelos not to stand for re-election; Schleifer and Yancopoulos named Co-Chairs

Dr. Vagelos will not stand for re-election at June 9, 2023 Annual Meeting; will serve as Chair until then.
February 3, 2023, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01 ◈ Earnings Releases

Regeneron Q4 revenue down 31% to $3.41B, core up 14%; GAAP EPS $10.50

Q4 total revenues $3.41B (-31% YoY); ex-REGEN-COV/Ronapreve up 14% to $3.02B.
January 9, 2023, 6:59 PM ET other material materiality 0.70 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Regeneron: FY2022 EYLEA US sales $6.26B (+8%), Q4 $1.50B (-3%); expects $30M IPR&D charge

FY2022 EYLEA US net product sales ~$6.26B (+8% YoY); Q4 2022 ~$1.50B (-3% YoY).
November 3, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Regeneron Q3 revenues down 15% to $2.94B; ex-REGEN-COV up 11%; EPS $11.66

GAAP diluted EPS $11.66 (Q3 2021: $14.33); non-GAAP $11.14 ($15.37).
August 3, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Regeneron Q2 revenue down 44% to $2.86B; core revenue up 20%; EPS $7.47 GAAP, $9.77 non-GAAP

Excluding REGEN-COV, total revenue grew 20% to $2.849B, driven by EYLEA ($1.62B +14%) and Dupixent ($2.09B +40%).
June 2, 2022, 7:59 PM ET other material materiality 0.85 positive item 1.01

Regeneron enters amended deal with Sanofi for full rights to Libtayo; pays $900M upfront

Regeneron gains sole worldwide rights to develop and commercialize Libtayo, effective upon regulatory approvals.
May 4, 2022, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Regeneron Q1 revenue up 17% to $2.97B; non-GAAP EPS $11.49, GAAP EPS $8.61; Dupixent +43%

Total revenue $2.97B (+17% YoY); ex-REGEN-COV revenue +25%; GAAP net income $974M, diluted EPS $8.61.
February 4, 2022, 6:59 PM ET earnings materiality 0.85 neutral item 2.02 item 9.01

Regeneron Q4 revenue surges 104% to $4.95B; REGEN-COV writedown $232M

Q4 GAAP diluted EPS $19.69 vs $10.24; non-GAAP EPS $23.72 vs $9.53.
January 10, 2022, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Regeneron reports preliminary FY2021 U.S. EYLEA sales of $5.79B, REGEN-COV sales of $5.82B

EYLEA FY2021 U.S. net product sales ~$5.79B (+17% YoY); Q4 sales ~$1.54B (+15% YoY).
November 4, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Regeneron Q3 revenues $3.45B (+51% YoY); GAAP EPS $14.33, non-GAAP $15.37

Total revenues $3.45B, up 51% YoY; GAAP net income $1.63B ($14.33 diluted EPS); non-GAAP net income $1.77B ($15.37 diluted EPS).
September 16, 2021, 7:59 PM ET other material materiality 0.90 positive item 1.01

Regeneron to supply 1.4M additional REGEN-COV doses to U.S. Government for $2.94B

Amendment obligates U.S. Government to buy 1.4 million doses at $2,100 each, totaling $2.94 billion.
August 5, 2021, 7:59 PM ET earnings materiality 0.90 positive item 2.02 item 9.01

Regeneron Q2 revenue up 163% to $5.14B; GAAP EPS $27.97; EYLEA sales record $1.42B

Total revenues $5.14B (+163% YoY) including $2.59B REGEN-COV; core revenue ex-REGEN-COV +22%.